{"address1": "5750 Explorer Drive", "address2": "Suite 404", "city": "Mississauga", "state": "ON", "zip": "L4W 0A9", "country": "Canada", "phone": "905-602-5840", "website": "https://www.cipherpharma.com", "industry": "Drug Manufacturers\u2014Specialty & Generic", "industryDisp": "Drug Manufacturers\u2014Specialty & Generic", "sector": "Healthcare", "longBusinessSummary": "Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome. The company's licensed products comprise Absorica, an oral retinoid indicated for the treatment of severe recalcitrant nodular acne; Lipofe indicated as adjunctive therapy to diet to reduce triglycerides in adult patients with severe hypertriglyceridemia; and Conzip, an opioid agonist indicated for the management of moderate to moderately severe chronic pain in adults. Its pipeline products include CF-101 for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine for treatment of onychomycosis; and DTR-001, a tattoo removal cream. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Mississauga, Canada.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Craig J. Mull", "title": "Interim CEO & Chairman", "fiscalYear": 2021, "totalPay": 72251, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Diane  Gajewczyk", "title": "VP of Scientific & Medical Affairs", "fiscalYear": 2021, "totalPay": 210191, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bryan  Jacobs", "title": "Chief Financial Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Emilio  Presti", "title": "Director of Sales & Marketing", "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1640908800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.4, "open": 2.4, "dayLow": 2.4, "dayHigh": 2.4, "regularMarketPreviousClose": 2.4, "regularMarketOpen": 2.4, "regularMarketDayLow": 2.4, "regularMarketDayHigh": 2.4, "payoutRatio": 0.0, "beta": 1.046683, "trailingPE": 2.4, "forwardPE": 4.8, "volume": 18945, "regularMarketVolume": 18945, "averageVolume": 4138, "averageVolume10days": 4310, "averageDailyVolume10Day": 4310, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "marketCap": 62068084, "fiftyTwoWeekLow": 1.06, "fiftyTwoWeekHigh": 5.38, "priceToSalesTrailing12Months": 3.0020838, "fiftyDayAverage": 2.5516, "twoHundredDayAverage": 2.45435, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "enterpriseValue": 31778056, "profitMargins": 1.2883201, "floatShares": 23568608, "sharesOutstanding": 25077500, "sharesShort": 11427, "sharesShortPriorMonth": 48425, "sharesShortPreviousMonthDate": 1477872000, "dateShortInterest": 1480464000, "sharesPercentSharesOut": 0.0004, "heldPercentInsiders": 0.42654, "heldPercentInstitutions": 0.002, "shortRatio": 0.97, "impliedSharesOutstanding": 0, "bookValue": 2.557, "priceToBook": 0.9386, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1672444800, "earningsQuarterlyGrowth": 6.004, "netIncomeToCommon": 26636000, "trailingEps": 1.0, "forwardEps": 0.5, "enterpriseToRevenue": 1.537, "enterpriseToEbitda": 2.659, "52WeekChange": 0.3872832, "SandP52WeekChange": 0.046755195, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "CPHRF", "underlyingSymbol": "CPHRF", "shortName": "CIPHER PHARMACEUTICALS INC", "longName": "Cipher Pharmaceuticals Inc.", "firstTradeDateEpochUtc": 1138890600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "33ee6a68-9bd5-3305-98c7-75445d99f34d", "messageBoardId": "finmb_8201659", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.4, "targetHighPrice": 5.59, "targetLowPrice": 5.59, "targetMeanPrice": 5.59, "targetMedianPrice": 5.59, "recommendationMean": 1.0, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 1, "totalCash": 28836000, "totalCashPerShare": 1.15, "ebitda": 11951000, "totalDebt": 428000, "quickRatio": 3.804, "currentRatio": 4.073, "totalRevenue": 20675000, "debtToEquity": 0.668, "revenuePerShare": 0.815, "returnOnAssets": 0.11012, "returnOnEquity": 0.51732, "grossProfits": 16683000, "freeCashflow": 4701250, "operatingCashflow": 10575000, "earningsGrowth": 6.16, "revenueGrowth": -0.161, "grossMargins": 0.80692, "ebitdaMargins": 0.57804, "operatingMargins": 0.53446, "financialCurrency": "USD", "trailingPegRatio": null}